Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.55 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668182 | 1.00 | GPR119 (0.64) | GPR119HDAC4HDAC6USP30DGAT2 | |
| SCHEMBL3638282 | 0.94 | GPR119 (0.69) | GPR119HDAC4HDAC6USP30PIK3CD | |
| SCHEMBL4943304 | 0.84 | HDAC6 (0.54) | GPR119HDAC4HDAC6USP30DGAT2 | |
| SCHEMBL3674391 | 0.84 | HDAC6 (0.54) | GPR119HDAC4HDAC6USP30DGAT2 | |
| SCHEMBL242088 | 0.82 | USP30 (0.68) | GPR119HDAC4HDAC6USP30PARP1 | |
| SCHEMBL242087 | 0.82 | USP30 (0.68) | GPR119HDAC4HDAC6USP30PARP1 | |
| SCHEMBL4921150 | 0.82 | USP30 (0.71) | HDAC4HDAC6USP30PARP1 | |
| SCHEMBL4924196 | 0.82 | USP30 (0.71) | HDAC4HDAC6USP30PARP1 | |
| SCHEMBL994594 | 0.82 | USP30 (0.71) | HDAC4HDAC6USP30PARP1 | |
| SCHEMBL3730320 | 0.81 | HDAC4 (0.55) | HDAC4HDAC6USP30DGAT2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | GPR119 655/4885HDAC4 652/4885HDAC6 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.